Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data th...
Main Authors: | Laura García-Quintanilla, Andrea Luaces-Rodríguez, María Gil-Martínez, Cristina Mondelo-García, Olalla Maroñas, Víctor Mangas-Sanjuan, Miguel González-Barcia, Irene Zarra-Ferro, Pablo Aguiar, Francisco J. Otero-Espinar, Anxo Fernández-Ferreiro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/11/8/365 |
Similar Items
-
Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina
by: Svjetlana Terzić, et al.
Published: (2015-08-01) -
Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
by: Kiss S, et al.
Published: (2018-08-01) -
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017-03-01) -
Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments
by: Anna-Kaisa Rimpelä, et al.
Published: (2018-12-01) -
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)